United Therapeutics Investing Cash Flow increased by 426.8% to $743.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 551.5%, from -$164.70M to $743.70M. Over 3 years (FY 2021 to FY 2025), Investing Cash Flow shows a downward trend with a 4.2% CAGR.
A negative value typically signals investment in future growth, while a positive value may indicate divestment or the maturity of a large investment portfolio.
This metric is the net total of all cash inflows and outflows related to investing activities, including capital expendi...
Most mature healthcare companies maintain a negative net investing cash flow due to ongoing R&D and infrastructure investment.
net_cash_from_investing| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$48.90M | -$235.90M | -$195.80M | -$359.20M | -$169.00M | -$94.00M | -$189.30M | -$221.10M | -$227.20M | -$313.40M | $0.00 | $735.30M | -$80.00M | -$114.90M | -$164.70M | -$299.90M | $140.90M | -$227.60M | $743.70M |
| QoQ Change | — | -382.4% | +17.0% | -83.5% | +53.0% | +44.4% | -101.4% | -16.8% | -2.8% | -37.9% | +100.0% | — | -110.9% | -43.6% | -43.3% | -82.1% | +147.0% | -261.5% | +426.8% |
| YoY Change | — | — | — | — | -245.6% | +60.2% | +3.3% | +38.4% | -34.4% | -233.4% | +100.0% | +432.6% | +64.8% | +63.3% | -122.4% | -274.9% | +222.6% | — | +551.5% |